Clinical trials in Galdakao

36 clinical trials in Galdakao, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Galdakao at a glance

clinical trials

Paediatric trials0
Research sites1

Quick filters

36 trials in Galdakao

Open in trial search

Systemic lupus erythematosus

Recruiting

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Systemic lupus erythematosus

Recruiting

BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

Investigational

BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sargramostim
Sponsor:Greenwich LifeSciences Inc.

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Janssen Cilag International

Contact Research Centre

Peripheral venous disease

Recruiting

Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

InvestigationalNo placebo

Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Allogeneic vein tissue segment, decellularised, with a functional valve perfused with autologous peripheral blood
Sponsor:VeriGraft AB

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:BI 1015550
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Quizartinib Dihydrochloride
Sponsor:Fundacion PETHEMA

Contact Research Centre

Colitis ulcerative

Recruiting

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Icotrokinra
Sponsor:Janssen Cilag International

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Smoking cessation therapy+1

Recruiting

Study on the Safety and Effectiveness of Cytisinicline for Helping Smokers Quit

Registered drugNo placebo

Study on the Safety and Effectiveness of Cytisinicline for Helping Smokers Quit

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cytisinicline
Sponsor:Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Galdakao

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on breast cancer treatments, including trials for HER2-positive and triple-negative variants. Research encompasses innovative therapies for pancreatic adenocarcinoma and colon cancer.

Advanced breast cancer therapies
Neoadjuvant chemotherapy approaches
Metastatic cancer treatments

Multiple trials evaluating novel drug combinations and targeted therapies for improved patient outcomes.

02 Pulmonary Medicine

Comprehensive research into pulmonary fibrosis and respiratory conditions, with studies examining new treatments for COPD and pulmonary embolism management.

Interstitial lung diseases
Progressive pulmonary conditions
Respiratory therapy optimization

Innovative approaches to improve lung function and patient quality of life.

03 Cardiovascular Studies

Investigations into cardiomyopathy prevention and treatment, including trials for acute coronary syndromes and peripheral arterial disease management.

Genetic cardiac conditions
Vascular disease treatments
Antiplatelet therapy optimization

Focus on preventive strategies and improved treatment protocols for heart conditions.

04 Additional Therapeutic Areas

Studies addressing endocrine disorders, including hypothyroidism and its effects. Research on hepatic conditions and smoking cessation therapies.

Liver disease management
Addiction treatment
Hormonal disorders

Diverse therapeutic approaches targeting various medical conditions.

Back to Spain All countries